Zydus Lifesciences on Saturday mentioned it has obtained approval from the US well being regulator to market generic anti-parasitic and leprosy medicines.
The corporate has obtained last approvals from the US Meals and Drug Administration (USFDA) for Ivermectin Tablets (3 mg) and Dapsone Tablets (25 mg and 100 mg), the Ahmedabad-based drug mentioned in a press release.
Ivermectin tablets are prescription anti-parasitic medicines primarily indicated for treating parasitic worm infections in people, particularly intestinal strongyloidiasis and onchocerciasis.
Dapsone tablets are indicated for the therapy of leprosy and dermatitis herpetiformis.
It acts as an anti-infective and antibacterial agent and is used to management pores and skin lesions in dermatitis herpetiformis and for leprosy.
Printed on February 28, 2026
Source link
#Zydus #Lifesciences #USFDA #nod #market #generic #drugs
